The present invention, in formula (1): [Formula 1] [In the formula, Ar, the following equation: [2] of (Wherein * denotes the binding site to the nitrogen atom, ** indicates the binding site of T) T is - be a (O) n -R There arylene linking group selected from the R, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 2 -C 6 alkenyl groups, C Here, thereof selected 2 -C 6 alkynyl group, tetrahydropyranyl group, tetrahydrothiopyranyl group, 1-oxo-tetrahydrothiopyranyl group, tetrahydropyranyl group and a 1,1-dioxo-tetrahydrothiopyranyl group groups may be substituted at the 1 to 3 substituents independently chosen from C 1 -C 6 alkoxy hydroxyl group, oxo group, and a halogen atom 0 or 1 to n X is , O, S (O) m, or NR 12, C = O CH, m is an integer from 0 to 2 wherein, R 1 is located at C 1 -C 3 alkyl or H R 2, is independently (the alkyl group, hydroxyl group, oxo group, C 1 -C 3 alkoxy group, R 4 and R 3 are, C 1 -C 3 alkyl and hydrogen C 1 -C 3 alkoxy C 1 -C 3 alkoxy R 2 and R 3 or, together with the urea structure including the nitrogen atom to which they are attached are selected from) may be substituted with 1 to 3 substituents selected independently from the group may, in the heterocycle may optionally be substituted with 1 to 3 independently selected from hydroxyl or oxo group that may form a 6-membered heterocyclic ring, or 5 are CH or N Y pharmaceutical compositions containing them as well as a prodrug, or their salt, a pharmaceutically acceptable composition comprising a compound represented by the formula: are provided.本発明により、式(1):【化1】[式中、Arは、下式:【化2】(式中、*は窒素原子への結合部位示し、**はTの結合部位を示す)から選択されるアリーレン連結基であり;Tは-(O)n-Rであり;Rは、C1-C6アルキル基、C3-C8シクロアルキル、C2-C6アルケニル基、C2-C6アルキニル基、テトラヒドロフラニル基、テトラヒドロチオピラニル基、1-オキソテトラヒドロチオピラニル基、1、1-ジオキソテトラヒドロチオピラニル基およびテトラヒドロピラニル基から選択され;ここで、これらの基は、水酸基、オキソ基、ハロゲン原子およびC1-C6アルコキシ基から独立に選択される1~3の置換基によりで置換されていてもよく;nは0または1であり;Xは、O、S(O)m、CH2、C=OまたはNR1であり、ここでmは0~2の整数であり、R1はHまたはC1-C3アルキルであり;R2、R3およびR4は、独立に、水素原子およびC1-C3アルキル(当該アルキル基は、水酸基、オキソ基、C1-C3アルコキシ基、C1-C3アルコキシC1-C3アルコキ
